A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
Status:
Recruiting
Trial end date:
2022-02-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability, and preliminary anti-tumor
activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178,
in patients with advanced cancers